Clinical TrialMay 21, 2026, 05:03 PM
Akari Therapeutics' AKTX-101 shows synergy with KRAS inhibitor
AI Summary
Akari Therapeutics announced positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, presented at the ASCO Annual Meeting 2026. The data highlighted synergistic cytotoxic activity of AKTX-101 in combination with a KRAS inhibitor (adagrasib) in KRAS-mutated pancreatic cancer models. This synergy, not observed with conventional TROP2 ADCs, suggests a differentiated mechanism for Akari's PH1 RNA spliceosome-modulating payload and expands the potential therapeutic opportunity for AKTX-101 in difficult-to-treat KRAS-driven cancers. The company aims to initiate a Phase 1 clinical trial for AKTX-101 by mid-2027.
Key Highlights
- AKTX-101, an ADC with PH1 payload, demonstrated synergistic cytotoxic activity with a KRAS inhibitor in pancreatic cancer models.
- The synergy was observed in KRAS G12D and G12C-driven pancreatic cancer cell lines.
- This synergistic inhibition was not seen with comparator Topoisomerase I-targeting TROP2 ADCs, which showed antagonism.
- The synergy is linked to PH1's unique ability to target pre-mRNA transcripts for degradation, including KRAS mutations.
- Data supports broader applicability of targeting RNA splicing for difficult-to-treat KRAS-driven cancers.
- Akari plans to initiate a Phase 1 first-in-human clinical trial for AKTX-101 by mid-2027.
Price Impact
More from AKTX